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stenosis; sevenly of cafcificatio~ across ago groups has not 10eon m ~ n ~  r 
M~'~PhO(~: Aor1~ valvos wore ObteiflO~l for analysis from 238 post mortems 
cortdu~ed bY a medical exammer on in~hvidgala no| known to haw aoff¢ 
valve disease (age range infant to 93 yeal's)~ For compem!on, 44 valves 
excised dunr~l i l .~¢ valve ~opt~_mont (AVR) wero a l~ analy~ed I~y atomic 
Ri~J~: Them w~ an e ~ a l  ~se m valve cak;ium Can. t  (not~ 
m P ,~ td~f og~ 60, M ~  ~ palled'Its ulXtelQoing AVR, 505 !~g/mg 
( ~  101~!~-), w~, 10 t i~  ~t JP r  Ih~n that O| O~o~en~fl~ without 
~ :  There is e~tat  in~rease in human aort~ v~lve cal¢ifi. 
calmn ~ age~ M~an ~ ~ a~ ~ 80 re in  be~w n~ose Of tl~e 
majority Ot paltenls with C~nt~! a~i'l¢ va~ StenO'~ts: 
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L877.51 ~ Natural Ni~to~/of Aom¢ Valve O l~ Afte~ 
. . . . . .  MRml Valve Oiil~mt!on 
M Va!un, A, Po~e~= Y ACtOr. Y ShaSta, B Vidr~e, A Sagre C a ~  an~ 
CarO~othorac~c Summon/D~oaglmen~ Rab~ Me~:a~ Center. Be~L~ns~n 
~u~d"  Lfftfe iS known aboul ~ natural h~s'forf at aotlie vane (AV) 
d~ease m plls ~ millrai valve (MV) operalmn. There is lack Of darity 
rngar~ng the ~ fo~ su~g~al lreatment Of rn~ AV disease whde :e~r ig  
the MV. We evak~ted the ~ Of AV ~ ar~ the need for further 
&V sutgeqt arnot~ p{s who undeP~ent MV operet~on (~su~Otomy or 
&~hog~.'One h~n£~! fifty o~e p~ (51 M. 10OF; mean age61 ± 13 yr.'s, 
range 35--89) were to l~ed afte~r MV ope~rat~on fo~ an at, erage period Of 13 
± ? ~.'s (r~mge 1-33). erie hu~d~d that one pts ;~r'~o) hod d~m~a~ heart 
~sease. The AV fu~3~n was assessed by an~ogrep~ and transtharac¢ 
Resu/ts. At the time Of MV operation 66 pts (44%) had AV disease: 7 pts 
(5%1 had ~ aon¢ stenos~ (AS), 64 pis (42%) n~ ~ .,~=~-~.,~on 
(AR) and a s~ng~e I~- (0_7%) moderate AR. At the end Of ~-up  period, 1 I0 
pts (73%) had &V d~ease: 3;2 pts (21%) n~tcl AS, 2 patients (1%) moderate 
AS. 2 pts (1%) severe AS. 96 pts (65%) mt~ AR, 6 pcs (4%) moderate AR 
~nd a smg~e pt (0.7%) severe AR_ AV d~sease had ptogresse£1 s~nd~:andy 
sw~-'e the operation m ordy 2 p~s. Su~ pts (3%1 needed AV reptacement after 
an average penod Of 21 ~ 's (range 15-33). No cfm~¢al factor coutcl ~ent~fy 
¢t~e pts wl~o t ro l l  eventuatly need AV replacement. 
~ n . -  Most o! the pls with rn~ AV d~sease at the t~me of MV oper- 
atie~ c~o not ~ to a severe disease. Thus, it seems that "prophytac~c" 
aortic valve replacement is not ~n(hcated. 
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~ Smoking and Are Associated W'dh the Obesity 
Progression of  Aort ic  Stenosis 
M.V Ngo. JS. Go~ner .  G. Chase. B.J Gersh, RD. F~'c~er, 
D.J. Femicola. Geongetewn Ur~e~ry Hosprtal. Veterans Administration 
Me(lcal Center. Washmglcn D. C , USA 
Backg~un~/: The flaMal history of aod=c stenosis (AS) includes a lafercy 
period followecl by an unp~bte  progress=on. Recent stuclles show an 
assoc, ation between nsk factors for atheroscleresis and the presence of AS. 
We hypothes,ze that atheroscterosrs nsk factors are a~so associated with the 
progression el AS. 
Methods: In a retrospective stu~3y, patients with a d~agnosts of AS IP#- 
continuous wave dappler and a f011ow-up sfuay of at least 6 months were 
included. Independent nsk factorS for the progression of AS were i~ntified 
by stepwise logistic regression analysis. 
Resutts: 123 patients were identified, and complet~ data were o~tained in 
87 patients (mean age 70.7 ¢ 10 yearS, 81% men. and mean foltow-up 2.54 ¢ 
1.6 years). The gradient was considered mild ( < 36 mmHg) in 61% of patients, 
and moderate (36--55 mmHg) in 31%. The mean rate of progression was 
6.3 ± 13 mmHg/year. Of those with mild AS, 36% progressed to moderate 
or severe over 2.9 ± 2.0 years. Independenf clinical factors associated w~th 
a progression of 5 mmHgh/r or greafor included a history of smoking (RR = 
3.06, 95°,o CI = 1.09-861, p = 0034) and a body mass index (kg/m 2) (RR = 
1.16, 95% CI = 1 O3-1.30. p = 0.013). There was an inverse correlation with 
total cholesterol (RR = 0.91 per 10 mg~dl increase. 95% CI = 0.827-0.g99, 
p = 0.0475) only when patients who were taking lipid-lowenng medications 
were included in the analysis. Hypertension, diabetes, age, gender and 
CAD (a history of revasculanzation, myocardial infarction or the presence 
of lesions >50% by catheterization) were not independently associated with 
the progression of AS. 
Conclusion: Body mass index and a history of smoking are independent 
predictors of significant progression of AS defined as -.5 mmHg/year. Inverse 
correlation with cholesterol may reflect cholesterol-lowering treatment as a 
marker for more seve'e disease assoc=alnd with a higher rat0 Of p~;)gress=on~ 
Among the group Of patients with m~ld AS, 36% progressed to read.vile or 
severe during follOw.up 
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veln'rhlvem mbol~ AIlioeklled or Not Wilh Pulmomm!!l 
Embolim 
R. Fa~/re FOr PREPIC tnve~tt~ltem: Clfn¢ Samf /~m,  B~n~.or~ France 
Background: Them was a ~ tO ovatuale t~a nsk/~nefrt ratio Of Low 
Molecular Weight Hepafin (LMWH) in the tnn~al tmalrnenl ~f Deep Veto 
Thronll:]~Si~ (DVI-) in presumed h,gh risk pat,c.~S 
, ~ .  LMI~ (Enoxapann, Enos) was cufnl~red to Ul~raclionateo 
Heparm (UFH) m a ran(lomtsed muftcenter trfft~ (PREPIC) in patients with 
vmlogcap~tcatly proven proximal DVT. A f"~:to~al desl~, was unCen~t con- 
comitantly to evaluate vena cava filter versus nc ~dter. Enox (s.c. I mgtkg b =.d) 
and UFH If.v, aPTl'-adiuSted) wer~ gn~m for II~, day~ and followed by oral 
ant~co~ nt  for at least 3 montl'~. Lung scar,~ t± p~tmo~l,y angmgrams) 
were performed s3,'stemai~lly at Cay 1 and .3zy 10. New asymptomalic 
or symptomatic PE at Day 10 was the primary endpoint. Symptomatic PE, 
recurrent DVT, major bleeding arid Death were bl~n~y evaluated at two years. 
~ .~ -<: 400 p~ants were included (195 En ~.,~, 205 UFH). The mean 
v~a-s 72 ylars. 49% of patients had a mltial PIE arid 90% had at least one 
I: .esumed rink faclor of PE./It day 10, new PE rate was 1.6% far Enox and 
42% to~r uFH (p = 0.14). At 2 years, symplomatic PE, recurrent DV'T ancl 
Death rate were sm~lar (3.g% vs 5.7%, 16.6% vs 15.8%, 20.6% vs 211%, 
respec~ve~,). Bleecling was ~ (8-5% vs 12%, NS). 
Con~uso'~.- Enoxapern~ appears at least a~ effective and sate as UFH 
=n the inltia frea~Tierit of proximal DVT associ;iled or not with Pulmonary 
Embessm i,; presumed high ask p'ttient5 
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~ Abbreviated Hospitalization Using a for gv'r Novel 
Low Molecular Weight Heparin, Ardeparln: Results 
of  a Randomized Control led T-ial 
SZ Gotdhaber. R.B Momson, L.L Diren. TH ee, Jr, Bnghamana 
Womens Hc,~at, BostOn, MA, USA 
Backgl~und: Although thelow molecular weight hepann, ardepann, has been 
recently approved for prevention of venous thromboembolism after fatal knee 
replacemerit. It has not been studied previously for treatment of acute deep 
vein thrombosis (DVT). 
Methods: We randomized 80 DVT pat~ts, (diagnosed by venous ultra- 
sound) to either a conventional 5 day hospifahzatmn with continuous mira- 
venous unfract~onated hepann (N = 39) (target PT'r 60-80 seconds) or to a 
2 day hospdalizalion with a low molecular weight hepann (N = 41), ardepilfin 
130 anti.Xa umts/kg suboulaneously twice dally (no laboratory monifomlg), 
until a target fNR of 20-3.0 and a steDle oral dose was achieved with war- 
farm. Patients were evaluated clrmcally with 2 and 6 week off~ce visits and 
uno'en~'ent follow-up venous ultrasound at 6 weeks, 
ResuffS: By ultrasound exammahon, 77% improved compared with base- 
line in the an:tepann group vemus 58% who imp~ with unfraCtionated 
hepann (p = 0.08). One major bleed occurred in each group. Median hospital 
charges were $6.500 aJ~ $?.815, respectively (p - 0.0001) Using a patient 
~tisfact=on sconng system where 1 = Excellent and 2 = Very Good, both 
groups reported an average score of t .3 for the care they recaived. 
Conc/usron. These data ff¢iicate that among properly selected patients, 
an abbrewated hospztahzatron usqng ardepann to manage DVT is effocIwo. 
safe. and much less costIy than conventional therapy. 
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[ -~  Pulmonary Embolism: Diagnosis With Helical 
Computed Tomography Angiography 
SD. Oanadli, A. Vedlard-Baron. F. Bruckert. O. Barre. F Mignon, T. Joseph. 
O. Oubourg, P. Lacombe. Pans V Unn, ersffy .~lmbrotse Pare Hospital. 
France 
Background: Diagnosing pulmon~;'v e .~bohsm (PE] ,e~,,a~ns a major clin=cel 
362A JACC Fcbm:u T 19')8 
problem. The purpose of this study la to evaluate prospectively the accuracy 
of helteel computed tomegraphy ongiogmphy in (HCTA) in acute pulmonary 
embolism (PE). 
Methods: 119 patients (59 :t= 15 yearn) with clinically suspected acute 
pulmonary embolism (PE) wore enrolled in this study. All patients underwent 
both HCTA (5 ram.collimation, ?.5.minis table speed. 2.7-ram effective slice 
thickness, 120-150 mt of contmt;t materiel at 4 ml/e rote) end digital selective 
pulmonary angiogmphy (DSA) within 12 hour~ of each other. All examinations 
were analyzed In consensus by two observem who were unaware of the 
findings in the reference otudy (DSA), 
Results: HCTA wee tochnlcally succeseful in 115/t 19 (96%) eaaee. BSA 
shewed PE in 41 patlent~ (34%)', ~9 in central veaeels (95,1%) nnd P in sub- 
segmental vessels (4,0%), The HCTA findings (~errataled well with DSA with 
two f~loe.positlve and one false.negative results, The prospective sensitivity 
of HCTA wee 95%, the specificity wan 98%, the positive predictive value were 
97% and the negative prodl0tlvo ~alue wee 97%, Both one false.positive and 
ono false.negative results were in sub~egmental level, One tree.negative 
mault had acute aortic hematoma detected by HCTA, 
Conoluslen: HCTA can accurately depict PE, Detection of aubsegmental 
clots remains a limitation of HCTA. oven if thin.alice thickness as ~,7 mm 
was used, 
9:15 
~ Prevention of Pulmonary Embolism by Inferior Vena 
Cave Filter In Patlente With Proximal Deed Vein 
Thrombosis 
FI, Faivm, For PREf~IC Inv~,~tt~nt, Char ~ in f  Vincent, f]e..~n~on, France 
B~IC'~IN/- Vane Cave Fillers (VCF) am increasingly used for the procreation 
of pulmonary embollt;m (PE), However, the beneflt/risk ratio el VCF has novor 
been aeseseed, 
MethoaL~: PREPIC was a mutticentor randemlsod chmcat eal ~n presumed 
high rt~;k paliente with proximal Deep Vein Thembosis (DVT) allocated to VCF 
or without (control, C), In addition, all patlonts received Hopafins followed 
by oral anticoagulant ot el least 3 months in both groups. Lung scans: 
(~ pulmonary angtograms) were performed at Day I and Day 10. Now 
asymptomatic or symptomatic PE at Day 10 was the pnmaP/ endpomt 
Symptomatic PE, ~oc, urront DVT and Drouth wore blindly evaluated for two 
yearn, 
Results: 400 patients worn included (200 VCF. 200 C). The moan ago 
was 72 years, 49% of patients had an initial PE and 90% hod at least one 
presumed risk factor of PE, At Day 10, PE rate was significantly lower in VCF 
group (1,1% vs 4.8% =n C, p = 0.03). At 2 years, PE was not stgnilicantly 
dllforent between VCF end C (3.4% vs 6.3%, p = 0.16): mecurront DVT was 
morn frequent in VCF group (20.8% vs 11.6%, p = 0.02): death rate was high 
tn both groups (21.6% vs 20.1%, NS). 
Conclusion: PREPIC Teal demonstrates the immediate fficacy o1 filter 
for pmeventlon of PE. However, because of the obson/ed excess of recurrent 
DVT and the absence of benefit on mortality in patients receiving filter, the 
systematic use of this device cs not to be recommended in this population. 
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~ 7  Recombinant Hlrudln In the Treatment of Heperln 
Induced Thromboeytopenla (HIT) Type II 
U, Janssons, A. Gmeinachor ~, P, Hanmth Universi~, Hospita! of Aachen. 
Germany; ~ Insitute for Immunolooy ancl Transfusion Mechcine. 
Emst.Montz-Amdt.Uni~rsi~, Gmi~u'nld. Germany 
HIT type It is a lifo-thmeatoning side-effect of hepadn therapy which is associ- 
ated with severn arterial and venous thromboembolic complications (TEC). 
Although affected patients require sustained pamentoral nticoagulation the 
mere suspicion of HIT type II mandates immediate cessation of hoparin ther- 
apy. Recombinant hirudln [rH] (Rofludan ~ , Hoechst, Germany) has recently 
been approved for treatment of HIT in Germany. 
Methods: All patients at our institution with clinical criteria of HIT and labo- 
ratory confirmation of heparin-induced antibodies were included in the study. 
350300 TP  la te Ic t c o u n ~  
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Hoperln we8 discontinued end replaced by rH according to a multi-center- 
study-protocol. RH wet; monitored by aPTT with a target range of 1.5-3,0 
fold prolongation of oPTT values at baseline. 
Results: 29 patients (59+ yearn, 19 main) were studied from 12/94 to 1/97, 
19 patients (05%) had TEC, Pletelet nadir under hepann therapy wse 60 :t- 
39 GIgWL, Significant sustained recovery of ptatelet values woe observed 
rapidly after start of rH, APTT values were wilhln forger values. Duration of 
rH treatment was 13 ~= 9 daye. no new TEC o~errad, 3 Patients died. noa~ 
of the deaths wee misted 1o rH. 
Conclrt~ion: Treatment of patients ~qffefing from HIT typ~ II wlth dd le~ing 
to rapid and sustained increase o1 plalelet ~'ounta while providing eun¢'~ent 
antleoagulstien, rH is t~ aafa and elfe¢tive alternative ant~-oagu!ant d~;I in 
patients with HIT type II, 
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~ l s  It Safe to Withhold or  Reveme Waffer!n ThemlW In 
Patients With Proethet!¢ Heart Va lwe After n ~ jor  
81~? 
K Ananthasebramaniam, J. Beeltie, V Javam, S, Bartok, H.S- Rosman. 
Henry FnM He~lrt and ~scutar Institute. Deln~l, &f~ch~ln, USA, 
The ask of thmmboembehsm when Wadann therapy is withhold Or ~velSed 
following a molar bleed in pmsthefio vahm patients is unknown. We identified 
29 patients (pts) with prosthetic head valves hosl)ilel[~l for a major bleed 
between 1990-1997, The aveffige age was 61 years with 16 males and 13 
females, 24 pts had St Jude valves, 4 had btoprosthehc valves and 2 each 
with ball Cage and tilting disc valves. V~htos were located in the mdrat posmon 
in 12 pts, aortic; tn 12, both mitml and aortK: in 4 and mcuspid in one. The 
average interval from valve surge W to the index bleed was 7 yearn. 26 pts 
had a gastrointestinal orretroperitoneat bleed, 2 had intrac~mal hemonhage 
and 1 had a subdurat hematoma. Average International Noemaltzed robe was 
3,3. Vitamin K was given to 5 and plasma to 7 to reverse antcoagulatton. 
Surgical intervention was required in 9 pts to treat bleeding, 4 o! ~t~,~m 
died in hospital. An additional 4 patients were lost to to;lewup. Average 
duration off anticeagutation was 15 days. ranging from 1 to 90. No pabent 
hod a clinically recognized thmmboembohc event while off anttcoagutat,on 
and them were no throraboembolic events in patients whose ant~Kjulahon 
was revemed. 23 patients had their wadann therapy resumed at the hma o| 
discharge. At 6 month tollowup. 10 patients had sustained recurrent bleeds. 
all gestmintsstinal, and one additional patient died. 
Conclusions: 1. Thromboembolic r~sk is low in patients with prosthetic 
heart valves and a major bleed when their anticoagulat~n is wtthhek:l or 
meversed. 2. Recurrent bleeding within 6 months o! resumption o! ant¢oag- 
ulation is common, 3. Although further study is warranted it appears that 
the ask of recunent bleeding after resumption of wartann may ouhvetgh the 
ask el thmemboembolism if wartann =s withheld in some patients ea~. after 
mesolution el major bleeding. 
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~ Differences Between Cardiologists and Generalists 
In Isehemlc Heart Disease Expenditures for 
Medicare Managed Care 
R.L. McNamara, N.R. Powe, T. Shelter, W. WoUer, G. Anderson. Johns 
Hopkins Un,versity, Baltimore, Maryland, USA 
Background." CapiV, tion paid to a pnncipal provider is becoming a more 
common method el payment under managed came. How elderly patients with 
ischomic heart disease (IHD) differ in cost under cardiologist (C) or generalist 
(G) care is unknown. 
Methods: We examined 1992 Medicare expenditures of 250,514 patients 
with IHD (ICD-9 codes 410-414). We defined pnncipal provider as the spe- 
cialty with the most Part B outpatient claims: 62% wore in the G (general 
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